44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT
University of Heidelberg, Heidelberg, DE
- Dr Sellner describes a retrospective study by the EBMT Lymphoma Working Party on safety and efficacy of idelalisib use before allogeneic stem cell transplantation (ASCT) in follicular lymphoma.
- He explains that the results were in line with previous similar studies in lymphoma. Progression-free survival at 12 months was 70%.
- The main findings of the study showed that idelalisib before ASCT was safe and it was an efficient bridging drug.